OncoMatch/Clinical Trials/NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Is NCT06500273 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Fludarabine and Cyclophosphamide for large b-cell lymphoma.
Treatment: Fludarabine · Cyclophosphamide · Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ — This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard first line therapy (R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) — first line
Participant has completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) as intended
Cannot have received: anti-CD19 targeted therapies
Prior treatment with anti-CD19 targeted therapies
Cannot have received: any anti-cancer treatment after end of treatment PET/CT and/or MRD testing
Anti-cancer treatment, including radiation, after end of treatment PET/CT and/or MRD testing is performed
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Genesis Cancer and Blood Institute · Hot Springs, Arkansas
- Alta Bates Summit Medical Center · Berkeley, California
- City of Hope · Duarte, California
- Cedars-Sinai Medical Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify